Accelerating Antibody Discovery for Challenging Fibrosis Targets
Advancing a first-in-class fibrosis program against complex biology
This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery approaches.
Inside the case study:
The biological and technical constraints that limited prior antibody discovery efforts
How Alloy’s ATX-Gx™ human transgenic mouse platform addressed high human–mouse homology
Advanced immunization strategies used to generate drug-like antibodies with cross-species reactivity
Execution tactics that preserved timelines when assay challenges emerged
Complete this form to download the case study and learn more about this collaboration
Accelerating antibody discovery for challenging fibrosis targets
Fibrosis targets present unique risks in biologics development, from limited reagent availability to difficulty generating differentiated, developable antibodies. This collaboration demonstrates how the right platforms, combined with disciplined execution, can reduce discovery risk and accelerate clinical momentum.
Discover how Alloy’s developability platform enables:
Early identification of biophysical liabilities that impact stability, aggregation, viscosity, and clearance
Integration of in vitro and in silico insights to guide smarter lead selection and engineering decisions
Confident comparison of candidates through benchmarking against approved and clinical-stage antibodies
Rapid iteration during lead optimization using high-throughput expression, QC, and re-screening workflows
Reduced downstream risk by advancing antibodies that balance biological activity with manufacturability and safety
